Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial

BACKGROUND: Treatment with non-steroidal anti-inflammatory drugs (NSAID) is a common component of treatment regimens for rheumatoid arthritis (RA). Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the treatment of RA at a dose of 90 mg. The current study further evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bickham, Kara, Kivitz, Alan J., Mehta, Anish, Frontera, Nancy, Shah, Sandhya, Stryszak, Paul, Popmihajlov, Zoran, Peloso, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977639/
https://www.ncbi.nlm.nih.gov/pubmed/27502582
http://dx.doi.org/10.1186/s12891-016-1170-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977639/
https://www.ncbi.nlm.nih.gov/pubmed/27502582
http://dx.doi.org/10.1186/s12891-016-1170-0

Ejemplares similares